GP3269: GNSA began Phase I safety testing in normal volunteers.

Gensia Inc. (GNSA), San Diego, Calif. Product: GP3269, adenosine regulating agent Indication: Epilepsy, pain control Status: GNSA began Phase I safety testing in normal volunteers. ...